Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Caracciolo

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Cancers|March 29, 2023
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Antonia Mancuso, Caterina Riillo, et al.
Leukemia|March 1, 2018
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activityNicola Amodio, Maria Angelica Stamato, Giada Juli, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 26, 2023
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myelomaFrancesca Scionti, Giada Juli, Roberta Rocca, et al.
Leukemia|August 19, 2018
miR-22 suppresses DNA ligase III addiction in multiple myelomaDaniele Caracciolo, Maria Teresa Di Martino, Nicola Amodio, et al.
Journal of Clinical Medicine|April 26, 2025
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's LymphomaGiuseppe Neri, Jessica Ielapi, Vincenzo Bosco, et al.
Journal of Translational Medicine|October 23, 2022
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid RhamnetinDaniele Caracciolo, Giada Juli, Caterina Riillo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic LeukemiaLuisa Giaccone, Ernesta Audisio, Benedetto Bruno, et al.
British Journal of Haematology|November 14, 2023
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphomaDaniele Caracciolo, Nicoletta Polerà, Beatrice Belmonte, et al.
Hematological Oncology|March 16, 2026
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific EngagerDaniele Caracciolo, Carlo Gentile, Sara Squillacioti, et al.
Journal of Hematology & Oncology|March 23, 2019
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myelomaMaria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Cancers|March 29, 2023
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Antonia Mancuso, Caterina Riillo, et al.
Leukemia|March 1, 2018
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activityNicola Amodio, Maria Angelica Stamato, Giada Juli, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 26, 2023
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myelomaFrancesca Scionti, Giada Juli, Roberta Rocca, et al.
Leukemia|August 19, 2018
miR-22 suppresses DNA ligase III addiction in multiple myelomaDaniele Caracciolo, Maria Teresa Di Martino, Nicola Amodio, et al.
Journal of Clinical Medicine|April 26, 2025
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's LymphomaGiuseppe Neri, Jessica Ielapi, Vincenzo Bosco, et al.
Journal of Translational Medicine|October 23, 2022
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid RhamnetinDaniele Caracciolo, Giada Juli, Caterina Riillo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic LeukemiaLuisa Giaccone, Ernesta Audisio, Benedetto Bruno, et al.
British Journal of Haematology|November 14, 2023
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphomaDaniele Caracciolo, Nicoletta Polerà, Beatrice Belmonte, et al.
Hematological Oncology|March 16, 2026
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific EngagerDaniele Caracciolo, Carlo Gentile, Sara Squillacioti, et al.
Journal of Hematology & Oncology|March 23, 2019
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myelomaMaria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, et al.
Pageof 8